Synergistic Anti-cancer Effect and Mechanism of FZKA Decoction Combined with Gefitinib on A549 Cells

Fang FANG; Wei SHI; Xiao-wei JIN; Wan-yin WU

doi:10.13422/j.cnki.syfjx.20192221

您当前的位置：

首页 >

文章列表页 >

Synergistic Anti-cancer Effect and Mechanism of FZKA Decoction Combined with Gefitinib on A549 Cells

Pharmacology | 更新时间：2021-02-09

- Synergistic Anti-cancer Effect and Mechanism of FZKA Decoction Combined with Gefitinib on A549 Cells
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 26, Issue 4, Pages: 95-101(2020)
- 作者机构：
  
  1.广西中医药大学　第一附属医院，南宁　 530000
  2.广东省中医院　芳村分院，广州　 510370
  3.云南省肿瘤医院，昆明　 650018
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20192221
  CLC： R22; R242; R2-031; R285.5
- Received：17 February 2019，
  
  Published Online：02 August 2019，
  
  Published：20 February 2020
- 稿件说明：
移动端阅览
Fang FANG, Wei SHI, Xiao-wei JIN, et al. Synergistic Anti-cancer Effect and Mechanism of FZKA Decoction Combined with Gefitinib on A549 Cells[J]. Chinese journal of experimental traditional medical formulae, 2020, 26(4): 95-101.
DOI：

Fang FANG, Wei SHI, Xiao-wei JIN, et al. Synergistic Anti-cancer Effect and Mechanism of FZKA Decoction Combined with Gefitinib on A549 Cells[J]. Chinese journal of experimental traditional medical formulae, 2020, 26(4): 95-101. DOI： 10.13422/j.cnki.syfjx.20192221.

摘要

目的：

通过体外体内实验观察扶正抗癌(FZKA)方联合吉非替尼(Gefitinib)对人肺腺癌A549细胞增殖，凋亡及侵袭转移能力的影响，并探讨研究其相关作用机制。

方法：

采用噻唑蓝(MTT)比色法检测空白组，FZKA方组(0.2，0.4，0.8，1.6，3.2 g·L

-1

)，Gefitinib组(10，20，40，60，80，100 μmol·L

-1

)的干预A549细胞24，48，72 h及FZKA方(2 g·L

-1

)联合Gefitinib(40 μmol·L

-1

)组干预A549细胞24 h的增殖能力；流式细胞术分析检测联合用药组细胞凋亡及周期的变化；划痕实验和transwell小室实验检测联合用药组的侵袭转移能力变化；蛋白免疫印迹法检测细胞联合用药组活化的半胱氨酸蛋白酶-3(cleaved-Caspase-3)，B淋巴细胞瘤-2(Bcl-2)，B淋巴细胞瘤-2相关X蛋白(Bax)，F-盒和含蛋白7的WD重复结构域(FBW7)及髓样细胞白血病-1(MCL-1)蛋白表达的变化情况。

结果：

与空白组比较，FZKA方，Gefitinib呈剂量依赖性、时间依赖性显著抑制A549细胞的增殖(

0.05)；与空白组比较，FZKA方组，Gefitinib组均能减弱细胞划痕愈合能力和侵袭能力，促进细胞凋亡(

0.05)，均能上调Bax，Caspase-3，FBW7蛋白表达，下调Bcl-2，MCL-1蛋白表达(

0.05)；与Gefitinib单独给药比较，FZKA方联合Gefitinib抑制A549细胞增殖能力和诱导细胞凋亡更明显(

0.05)；细胞划痕愈合能力与侵袭能力明显减弱(

0.05)；上调Bax，Caspase-3，FBW7蛋白表达，下调Bcl-2，MCL-1蛋白表达效果明显(

0.05)。

结论：

FZKA方与Gefitinib合用后比单用Gefitinib更能诱导A549细胞凋亡，抑制其增殖及侵袭转移能力更强，两者具有协同抗癌作用，其机制可能与调控FBW7/MCL-1通路相关。

Abstract

Objective:

To observe the effect of Fuzheng Kangai (FZKA) decoction combined with gefitinib on the cells proliferation

apoptosis

invasion and metastasis of human lung adenocarcinoma A549 cells

in vitro

and

in vivo

and relevant mechanisms.

Method:

The A549 cell proliferation of the control group

FZKA decoction groups (0.2

0.4

0.8

1.6

3.2 g·L

-1

)

Gefitinib groups (10

100 μmol·L

-1

) for 24

72 hours

and FZKA decoction (2 g·L

-1

) combined with Gefitinib (10 μmol·L

-1

) groups for 24 hours was detected by methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay. The changes of cell apoptosis

invasion and metastasis abilities of A549 cells were analyzed by flow cytometry

Wound Healing

transwell invasion assay. Western blot assay was used to examine the protein expressions of cleaved Caspase-3

B-cell lymphoma-2 (Bcl-2)

B-cell lymphoma-2 associated X (Bax)

F-box and WD repeat domain-containing (FBW7) and myeloid cell leukemia-1 (MCL-1)

in vitro

Result:

Compared with control group

FZKA decoction group and Gefitinib group inhibited the cell proliferation

cell apoptosis

cell invasion and metastasis abilities in a dose-dependent and time-dependent manner

and improve the protein expressions of Bax

Caspase-3

FBW7

but decreased the protein expressions of Bcl-2

MCL-1 (

0.05). Compared with treatment with Gefitinib alone

FZKA combined with Gefitinib inhibited the proliferation of A549 cells

and induced apoptosis more significantly (

0.05). Compared with treatment with Gefitinib alone

the cell scratch healing and invasion abilities were significantly reduced after combined treatment (

0.05). FZKA decoction combined with Gefitinib up-regulated Bax

Caspase-3 and FBW7 protein expressions

and down-regulated Bcl-2 and MCL-1 protein expressions compared with treatment with Gifitinib alone (

0.05).

Conclusion:

FZKA decoction combined with Gefitinib can inhibit the proliferation

invasion and metastasis

and induce apoptosis on A549 cells. The mechanism may be associated with the FBW7/MCL-1 pathway.

关键词

Keywords

references

F Bray , J Ferlay , I Soerjomataram , et al . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA: Cancer J Clin , 2018 ， 68 ( 6 )： 394 - 424 .

D Orgensztern , S Waqar , J Subramanian , et al . Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer [J]. J Thorac Oncol , 2012 ， 7 ( 10 )： 1485 - 1489 .

D B Costa , K S Nguyen , B C Cho , et al . Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to Gefitinib [J]. Clin Cancer Res , 2008 ， 14 ( 21 )： 7060 - 7067 .

D W Bell , I Gore , R A Okimoto , et al . Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR [J]. Nat Genet , 2005 ， 37 ( 12 )： 1315 - 1316 .

S Kobayashi , T J Boggon , T Dayaram , et al . EGFR mutation and resistance of non-small-cell lung cancer to gefitinib [J]. N Engl J Med , 2005 ， 352 ( 8 )： 786 - 792 .

M Inukai , S Toyooka , S Ito , et al . Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer [J]. Cancer Res , 2006 ， 66 ( 16 )： 7854 - 7858 .

J A Engelman , K Zejnullahu , T Mitsudomi , et al . MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling [J]. Science , 2007 ， 316 ( 5827 )： 1039 - 1043 .

K Suda , I Murakami , T Katayama , et al . Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer [J]. Clin Cancer Res , 2010 ， 16 ( 22 )： 5489 - 5498 .

M YE , Y ZHANG , X ZHANG , et al . Targeting FBW7 as a strategy to overcome resistance to targeted therapy in non-small cell lung cancer [J]. Cancer Res , 2017 ， 77 ( 13 )： 3527 - 3539 .

吴万垠，杨小兵，龙顺钦，等 . 扶正抗癌方联合吉非替尼治疗晚期非小细胞肺癌优势人群与非优势人群的比较 [J]. 时珍国医国药， 2013 ， 24 ( 9 )： 2152 - 2154 .

李龙妹，吴万垠，王苏美，等 . 扶正抗癌方诱导H1650细胞凋亡的分子机制 [J]. 中国实验方剂学杂志， 2016 ， 22 ( 14 )： 106 - 110 .

李龙妹，吴万垠，龙顺钦，等 . 扶正抗癌方抑制PC9细胞转移的分子机制 [J]. 辽宁中医杂志， 2016 ( 10 )： 2021 - 2025，2237 .

李龙妹，杨小兵，吴万垠 . 扶正抗癌方通过SAPK/JNK-Sp1通路对H1650细胞增殖的影响 [J]. 广东医学， 2016 ， 37 ( 14 )： 2069 - 2072 .

杨小兵，陈晓，吴万垠，等 . 扶正抗癌方联合吉非替尼对肺癌A549细胞的影响及机制 [J]. 中国中西医结合杂志， 2016 ， 36 ( 11 )： 1340 - 1344 .

李龙妹，吴万垠 . 扶正抗癌方抑制A549转移的分子机制 [J]. 中华中医药杂志， 2016 ， 31 ( 11 )： 4759 - 4762 .

杨小兵，龙顺钦，邓宏，等 . 207例晚期非小细胞肺癌中医证型分布特点 [J]. 辽宁中医药大学学报， 2013 ， 15 ( 3 )： 188 - 190 .

杨小兵，庄媛媛，龙顺钦，等 . 扶正抗癌方对吉非替尼在肺癌H1650、A549细胞上的增效作用 [J]. 广东医学， 2018 ， 39 ( 20 )： 3002 - 3009 .

黎金华，吴万垠，杨小兵 . 扶正抗癌方通过PTEN/PI3K/Bad通路调控肺癌A549细胞增殖与凋亡 [J]. 中国实验方剂学杂志， 2017 ， 23 ( 21 )： 98 - 103 .

I E Wertz , S Kusam , C Lam , et al . Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7 [J]. Nature , 2011 ， 471 ( 7336 )： 110 - 114 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Reduning Injection， Shenfu Injection Combined with Gefitinib on Proliferation， Stemness Characteristics and Metabolism of Non-small Cell Lung Cancer Cells

Synergistic Antithrombotic Action Between Astragalosides And Total Saponins Of Paeonia

Effect of Compatibility on Anti-ischemia of Rats with Astragalasides and Total Saponins of Pnanx notoginseng

Effect of Honokiol Combined with Artemisinin on Cell Cycle Arrest in CNE-2 Cells

Study on the Synergistic Effect between and in Control of Diabetic Cardiopathy

Related Author

ZHANG Haibo

CHEN Yadong

CHANG Xuesong

LIU Yihong

LEI Chenjing

MA Changju

DING Lina

YU Yaya

Related Institution

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine （Guangdong Provincial Hospital of Chinese Medicine）

Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome

HongKong-Macao Joint Lab on Chinese Medicine and Immune Disease Research

The Second Clinical College of Guangzhou University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰